Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2 Study of PTX-100 Monotherapy in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

NCT06854653 is registered in ClinicalTrials.gov with Prescient Therapeutics, Ltd. as lead sponsor.

NCT NCT06854653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06854653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2 Study of PTX-100 Monotherapy in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Lead sponsor
Prescient Therapeutics, Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 28, 2025
Completion date
June 30, 2028
Enrollment
115 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ctcl